Stryker Corp (SYK)

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

Symbol: SYK
Exchange: NYSE
Sector: Healthcare
Industry: Medical Devices
Market cap: $105.65B
52 week range: 267 - 392.55

Valuation

Share price: $275.43 (close of 2026-10-02)
P/E (TTM): 28.31x
Price to book: 4.40x
Price to free cash flow: 22.47x
Enterprise value: $117.20B
Book value per share: $62.54

Price performance

Period	Change
1 day	+0.90%
5 days	+1.13%
1 month	-11.77%
3 months	-15.65%
6 months	-16.92%
Year to date	-21.63%
1 year	-24.83%
3 years	+0.58%
5 years	+2.69%
10 years	+136.60%

Members of Congress who disclosed SYK trades

Thomas Kean · Gilbert Ray Cisneros · Jared Moskowitz · Jefferson Shreve · Julia Letlow · Robert Bresnahan · Alan Armstrong · Julie Johnson

Super investors holding SYK

Terry Smith (Fundsmith LLP) · Ken Griffin (Citadel) · AKO Capital (AKO Capital LLP) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc)

Profitability and growth

Return on equity: 14.48%
Return on invested capital: 10.57%
Return on assets: 6.78%
Return on capital employed: 12.21%
Gross margin: 63.96%
Net margin: 12.92%
EBITDA margin: 25.72%
Revenue growth: 11.16%
Net income growth: 8.45%
Free cash flow growth: 22.83%

Cash flow and balance sheet

Free cash flow yield (TTM): 4.45%
Current ratio: 2.16x
Net debt to EBITDA: 1.65x

Latest reported year

Period end: 2025-12-31
Fiscal year: 2025
Revenue: $25.12B
Cost of revenue: $9.05B
Gross profit: $16.07B
EBITDA: $6.46B
Net income: $3.25B
Earnings per share: $8.49
Research and development: $1.62B
Shares outstanding: 382.20M

Income statement by year

Period end	Revenue	Gross profit	Net income	EPS
2025-12-31	$25.12B	$16.07B	$3.25B	$8.49
2024-12-31	$22.59B	$14.44B	$2.99B	$7.86
2023-12-31	$20.50B	$13.06B	$3.17B	$8.34
2022-12-31	$18.45B	$11.58B	$2.36B	$6.23
2021-12-31	$17.11B	$10.97B	$1.99B	$5.29
2020-12-31	$14.35B	$9.06B	$1.60B	$4.26
2019-12-31	$14.88B	$9.70B	$2.08B	$5.57
2018-12-31	$13.60B	$8.94B	$3.55B	$9.50
2017-12-31	$12.44B	$8.18B	$1.02B	$2.73
2016-12-31	$11.32B	$7.50B	$1.65B	$4.40

Margins and returns by year

Period end	Gross margin	Net margin	Return on equity	Return on capital
2025-12-31	63.96%	12.92%	14.48%	10.57%
2024-12-31	63.91%	13.25%	14.51%	10.43%
2023-12-31	63.70%	15.44%	17.02%	11.81%
2022-12-31	62.76%	12.78%	14.19%	9.04%
2021-12-31	64.11%	11.66%	13.40%	9.25%
2020-12-31	63.11%	11.14%	12.22%	7.60%
2019-12-31	65.14%	13.99%	16.26%	11.25%
2018-12-31	65.72%	26.12%	30.29%	14.18%
2017-12-31	65.73%	8.20%	10.22%	8.70%
2016-12-31	66.26%	14.54%	17.25%	14.53%

Cash and debt by year

Period end	Cash	Debt
2025-12-31	$4.01B	$14.86B
2024-12-31	$3.65B	$12.19B
2023-12-31	$2.97B	$10.90B
2022-12-31	$1.84B	$11.86B
2021-12-31	$2.94B	$12.47B
2020-12-31	$2.94B	$13.23B
2019-12-31	$4.42B	$10.23B
2018-12-31	$3.70B	$8.49B
2017-12-31	$2.79B	$6.59B
2016-12-31	$3.38B	$6.69B

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	$4.28B	$243.00M
2024-12-31	$3.49B	$229.00M
2023-12-31	$3.14B	$205.00M
2022-12-31	$2.04B	$168.00M
2021-12-31	$2.74B	$171.00M
2020-12-31	$2.79B	$142.00M
2019-12-31	$1.54B	$127.00M
2018-12-31	$2.04B	$119.00M
2017-12-31	$961.00M	$113.00M
2016-12-31	$1.43B	$97.00M

Dividend history

Most recent payment: 2026-09-30
Paid in the last twelve months: $3.52

Payment date	Dividend per share
2026-09-30	$0.88
2026-06-30	$0.88
2026-03-31	$0.88
2025-12-31	$0.88
2025-09-30	$0.84
2025-06-30	$0.84
2025-03-31	$0.84
2024-12-31	$0.84

Investor relations

Next earnings report

Next confirmed report: 2026-10-29
Consensus EPS estimate: $3.60

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-07-30	Jun/2026	$3.46
2026-04-30	Mar/2026	$2.98
2026-01-29	Dec/2025	$4.40
2025-10-30	Sep/2025	$3.14
2025-07-31	Jun/2025	$3.06
2025-05-01	Mar/2025	$2.73
2025-01-28	Dec/2024	$3.87
2024-10-29	Sep/2024	$2.78

Filings and sources

Company website: stryker.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Boston Scientific Corp (BSX) · Medtronic plc (MDT) · Edwards Lifesciences Corp (EW) · Abbott Laboratories (ABT) · Dexcom Inc (DXCM) · GE HealthCare Technologies Inc. (GEHC) · Universal Health Services Inc (UHS) · DaVita Inc. (DVA)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades